[8-K] bioAffinity Technologies, Inc. Warrant Reports Material Event

Rhea-AI Filing Summary

Greystone Housing Impact Investors LP (GHI) filed a Form 8-K dated July 23, 2025. The lone material disclosure is that the partnership issued a press release announcing an investor conference call on August 7, 2025 at 4:30 p.m. ET to review its Q2 2025 results. No financial figures, guidance, or qualitative business updates are included in this filing. The company also furnished Exhibit 99.1 (the press release itself, not provided here) and Exhibit 104 (cover-page Inline XBRL). Accordingly, this 8-K serves only as a procedural notice of the upcoming earnings discussion.

Insights

Financial Analyst

TL;DR: Procedural 8-K; simply schedules Aug 7 earnings call—no financial impact disclosed.

The filing contains no operational or financial data, only the date and time of the Q2 2025 earnings call. Such notices are routine and carry negligible valuation implications. Investors should wait for the actual Q2 release to assess revenue, margins, and portfolio performance. Until then, the risk-return profile of GHI remains unchanged by this disclosure.

false 0001712762 0001712762 2025-07-23 2025-07-23 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2025-07-23 2025-07-23 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2025-07-23 2025-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 23, 2025

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41463		46-5211056
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Title of each class		Trading Symbols		Name of each exchange on which registered
Common Stock, par value $0.007 per share		BIAF		The Nasdaq Stock Market LLC (Nasdaq Capital Market)
Warrants to purchase Common Stock		BIAFW		The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On July 23, 2025, bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) issued a press release announcing the release of a new case study in which CyPath® Lung identified a Stage 1A neuroendocrine tumor in the lung after PET scan, bronchoscopies and a serum tumor marker test suggested it was non-cancerous inflammation.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by bioAffinity Technologies, Inc., dated July 23, 2025
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 23, 2025	BIOAFFINITY TECHNOLOGIES, INC.
	By:	/s/ Maria Zannes
	Name:	Maria Zannes
	Title:	President and Chief Executive Officer

-3-

FAQ

When will Greystone Housing Impact Investors LP (GHI) report Q2 2025 results?

August 7, 2025 at 4:30 p.m. ET via an investor conference call.

What type of document did GHI file on July 23, 2025?

A Form 8-K current report with the SEC.

Does the 8-K include any Q2 2025 financial figures for GHI?

No. The filing only announces the upcoming earnings call; it discloses no financial data.

What exhibits accompany this Form 8-K?

Exhibit 99.1 (press release dated July 23, 2025) and Exhibit 104 (cover-page Inline XBRL data file).

Is this filing considered material to GHI’s valuation?

The notice is routine; it does not provide new financial information likely to affect valuation.